These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25788373)

  • 1. Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?
    Eslam M; George J
    Hepatol Int; 2015 Jan; 9(1):5-8. PubMed ID: 25788373
    [No Abstract]   [Full Text] [Related]  

  • 2. Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents.
    Berzsenyi MD; Roberts SK
    J Gastroenterol Hepatol; 2010 Apr; 25(4):655-6. PubMed ID: 20492322
    [No Abstract]   [Full Text] [Related]  

  • 3. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5.
    Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F
    Gut; 2012 Nov; 61(11):1640-1. PubMed ID: 22345656
    [No Abstract]   [Full Text] [Related]  

  • 4. IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin.
    Giannini EG; Marenco S; Baldissarro I; Fazio V
    Aliment Pharmacol Ther; 2011 Aug; 34(3):398-400. PubMed ID: 21726252
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhancing predictive ability of IL28B-SNPs for SVR in HCV.
    Amanzada A; Schneider S; Moriconi F; Mihm S; van Thiel DH; Ramadori G
    Aliment Pharmacol Ther; 2012 Jan; 35(2):317-8. PubMed ID: 22172087
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic Hepatitis C Infection in Children.
    Pham YH; Rosenthal P
    Adv Pediatr; 2016 Aug; 63(1):173-94. PubMed ID: 27426900
    [No Abstract]   [Full Text] [Related]  

  • 7. Definition of response to antiviral therapy in chronic hepatitis C.
    Craxï A; Cammà C; Giunta M
    J Hepatol; 1999; 31 Suppl 1():160-7. PubMed ID: 10622580
    [No Abstract]   [Full Text] [Related]  

  • 8. Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin: Reappearance of references published in 2005-2009.
    Gelderblom HC; Beld MG
    J Clin Virol; 2010 Jun; 48(2):150-1; author reply 152. PubMed ID: 20347385
    [No Abstract]   [Full Text] [Related]  

  • 9. HCV persistence: cure is still a four letter word.
    Feld JJ; Liang TJ
    Hepatology; 2005 Jan; 41(1):23-5. PubMed ID: 15690477
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C.
    Stättermayer AF; Hofer H; Ferenci P
    J Hepatol; 2012 Sep; 57(3):706; author reply 706-7. PubMed ID: 22748774
    [No Abstract]   [Full Text] [Related]  

  • 11. Boceprevir.
    Maddur H; Kwo PY
    Hepatology; 2011 Dec; 54(6):2254-7. PubMed ID: 22095684
    [No Abstract]   [Full Text] [Related]  

  • 12. [Quantification of hepatitis C virus RNA in serum].
    Kawai S; Yokosuka O
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):426-9. PubMed ID: 15359836
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of hepatitis C virus (HCV) genotype, HCV RNA load, and alanine aminotransferase level on reduction of HCV RNA after a single administration of interferon-alpha.
    Antonelli G; Riva E; Maggi F; Vatteroni ML; Simeoni E
    J Infect Dis; 1999 Oct; 180(4):1411-2. PubMed ID: 10479188
    [No Abstract]   [Full Text] [Related]  

  • 14. How to use virological tools for the optimal management of chronic hepatitis C.
    de Leuw P; Sarrazin C; Zeuzem S
    Liver Int; 2011 Jan; 31 Suppl 1():3-12. PubMed ID: 21205131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C.
    Soriano V; Vispo E; de Mendoza C; Labarga P; Plaza Z; Fernandez-Montero JV; Poveda E; Treviño A; Barreiro P
    Antivir Ther; 2013; 18(8):1033-5. PubMed ID: 23804629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
    Jenkins ET; Jensen DM
    Infect Dis Clin North Am; 2012 Dec; 26(4):879-91. PubMed ID: 23083821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus.
    Elsharkawy AM
    Aliment Pharmacol Ther; 2014 Mar; 39(5):543-4. PubMed ID: 24494842
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.
    Figlerowicz M; Sluzewski W; Kowala-Piaskowska A; Mozer-Lisewska I
    Eur J Pediatr; 2004 Apr; 163(4-5):265-7. PubMed ID: 14991399
    [No Abstract]   [Full Text] [Related]  

  • 20. Can we use the "C" word with confidence? Cure for chronic hepatitis C.
    Chen JY; Chung RT
    Gastroenterology; 2011 Mar; 140(3):766-8. PubMed ID: 21256845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.